Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

141. Treatment of Hypertension in Association With Heart Failure

Treatment of Hypertension in Association With Heart Failure VII. Treatment of Hypertension in Association With Heart Failure | Hypertension Canada Guidelines Subgroup Members: Simon W. Rabkin, MD; Gordon W. Moe, MD, MSc; Jonathan G. Howlett, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia, BSc MD MSc (...) unless adverse effects become manifest (Grade B). Hypertension persisting after development of heart failure is associated with more frequent adverse outcomes such as hospitalization . As outlined below, hypertension treatment regimens in patients with heart failure (HF) should generally include ACE inhibitors (or ARBs), beta-blockers and MRAs in selected patients. Consistent with the Canadian Cardiovascular Society (CCS) recommendations on heart failure , dosages of ACE inhibitors and ARBs should

2018 Hypertension Canada

142. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. (PubMed)

Transcatheter Mitral-Valve Repair in Patients with Heart Failure. Among patients with heart failure who have mitral regurgitation due to left ventricular dysfunction, the prognosis is poor. Transcatheter mitral-valve repair may improve their clinical outcomes.At 78 sites in the United States and Canada, we enrolled patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical (...) therapy. Patients were randomly assigned to transcatheter mitral-valve repair plus medical therapy (device group) or medical therapy alone (control group). The primary effectiveness end point was all hospitalizations for heart failure within 24 months of follow-up. The primary safety end point was freedom from device-related complications at 12 months; the rate for this end point was compared with a prespecified objective performance goal of 88.0%.Of the 614 patients who were enrolled in the trial

2018 NEJM

143. Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery (PubMed)

Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery Heart failure is the leading cause of death in the western world and as such, there is a great need for new therapies. Heart failure has a variable presentation in patients and a complex etiology; however, it is fundamentally a condition that affects the mechanics of cardiac contraction, preventing the heart from generating sufficient cardiac output under normal operating pressures. One (...) of the major issues hindering the development of new therapies has been difficulties in developing appropriate in vitro model systems of human heart failure that recapitulate the essential changes in cardiac mechanics seen in the disease. Recent advances in stem cell technologies, genetic engineering, and tissue engineering have the potential to revolutionize our ability to model and study heart failure in vitro. Here, we review how these technologies are being applied to develop personalized models

Full Text available with Trip Pro

2018 Frontiers in cardiovascular medicine

144. Evaluation and Management of Right-Sided Heart Failure

Evaluation and Management of Right-Sided Heart Failure Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 Free Access article Share on Jump to Free Access article (...) Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association , MD, Chair , MD, MS, FAHA, Co-Chair , MD , MD, PhD, FAHA , MD , MD , MD, MS , MD, MPH, FAHA , MD , MD, PhD, FAHA , and MD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia Marvin A. Konstam , Michael S. Kiernan , Daniel Bernstein , Biykem Bozkurt , Miriam

Full Text available with Trip Pro

2018 International Society for Heart and Lung Transplantation

145. Chronic heart failure in adults: diagnosis and management

Chronic heart failure in adults: diagnosis and management Chronic heart failure in adults: diagnosis Chronic heart failure in adults: diagnosis and management and management NICE guideline Published: 12 September 2018 nice.org.uk/guidance/ng106 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Chronic heart failure in adults: diagnosis and management (NG106) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

146. The impact of high-intensity inspiratory muscle training on exercise capacity and inspiratory muscle strength in heart failure with reduced ejection fraction: a systematic review and meta-analysis

The impact of high-intensity inspiratory muscle training on exercise capacity and inspiratory muscle strength in heart failure with reduced ejection fraction: a systematic review and meta-analysis Inspiratory muscle training (IMT) improves prognostic clinical variables in patients with heart failure. However, the optimal intensity for increasing those outcomes remains unclear. Thus, we aimed to determine whether high-intensity inspiratory muscle training (HIIMT) improves exercise capacity (...) and respiratory muscle strength in patients with heart failure with reduced ejection fraction (HFrEF).We searched for randomized controlled clinical trials at MEDLINE, the Cochrane Central Register of Controlled Trials, the Physiotherapy Evidence Database, SciELO and CINAHL from the earliest date available to May 2018. Primary studies on HIIMT against low-intensity IMT or sham-IMT that evaluated exercise capacity and inspiratory muscle strength were included. Two independent reviewers evaluated

2018 EvidenceUpdates

147. Myocardial expression of the anaphylatoxin receptor C3aR is associated with cardiac inflammation and prognosis in patients with non‐ischaemic heart failure (PubMed)

Myocardial expression of the anaphylatoxin receptor C3aR is associated with cardiac inflammation and prognosis in patients with non‐ischaemic heart failure The aim of this study is to analyse the prognostic value of complement anaphylatoxin receptors in patients with non-ischaemic cardiomyopathy undergoing endomyocardial biopsy.In 102 patients (72.5% male patients, median age 54 years) with non-ischaemic cardiomyopathy, myocardial expression of C3aR was assessed among other parameters (...) . The primary study endpoint was a composite of death, heart transplantation, heart failure-related re-hospitalization, and deterioration of left ventricular ejection fraction within a mean follow-up of 11.9 months. The number of cells, which stained positive for C3aR, was significantly increased in patients with inflammatory compared with non-inflammatory cardiomyopathy (1.75 ± 0.31 cells in inflammatory cardiomyopathy vs. 0.94 ± 0.26 in non-inflammatory cardiomyopathy, P = 0.049). Subsequently, positive

Full Text available with Trip Pro

2018 ESC heart failure

148. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. (PubMed)

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and improve outcomes for patients with worsening chronic heart failure and underlying coronary artery disease.In this double-blind, randomized trial, 5022 patients who had chronic heart failure, a left (...) ventricular ejection fraction of 40% or less, coronary artery disease, and elevated plasma concentrations of natriuretic peptides and who did not have atrial fibrillation were randomly assigned to receive rivaroxaban at a dose of 2.5 mg twice daily or placebo in addition to standard care after treatment for an episode of worsening heart failure. The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. The principal safety outcome was fatal bleeding

2018 NEJM

149. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. (PubMed)

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heart failure decompensation. We aimed to investigate the efficacy of our remote patient management intervention (...) on mortality and morbidity in a well defined heart failure population.The Telemedical Interventional Management in Heart Failure II (TIM-HF2) trial was a prospective, randomised, controlled, parallel-group, unmasked (with randomisation concealment), multicentre trial with pragmatic elements introduced for data collection. The trial was done in Germany, and patients were recruited from hospitals and cardiology practices. Eligible patients had heart failure, were in New York Heart Association class II or III

2018 Lancet

150. Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial (PubMed)

Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial Readmissions for heart failure (HF) are a major burden. We aimed to assess whether the extent of improvement in pulmonary fluid content (ΔPC) during HF hospitalization evaluated by lung impedance (LI), or indirectly by other clinical and laboratory parameters, predicts readmissions.The present study is based on pre-defined secondary analysis of the IMPEDANCE-HF extended trial (...) with ΔPC ≤ median for all parameters evaluated in both study groups with the most pronounced difference predicted by LI (P < 0.01). Net reclassification improvement analysis showed that adding LI to the traditional clinical and laboratory parameters improved the predictive power significantly.The extent of ΔPC improvement, primarily the LI based, during HF-hospitalization, and study group allocation strongly predicted readmission and event-free survival time.© 2018 The Authors. ESC Heart Failure

Full Text available with Trip Pro

2018 ESC heart failure

151. Iron deficiency in chronic heart failure: case‐based practical guidance (PubMed)

Iron deficiency in chronic heart failure: case‐based practical guidance In patients with chronic heart failure, iron deficiency, even in the absence of anaemia, can aggravate the underlying disease and have a negative impact on clinical outcomes and quality of life. The 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure recognize iron deficiency as a co-morbidity in chronic heart failure and recommend iron status screening in all (...) newly diagnosed patients with chronic heart failure. Furthermore, the guidelines specifically recommend considerations of intravenous iron therapy, ferric carboxymaltose, for the treatment of iron deficiency. However, in spite of these recommendations, iron deficiency remains often overlooked and undertreated. This may be due, in part, to the lack of clinical context and practical guidance accompanying the guidelines for the treating physician. Here, we provide practical guidance complemented

Full Text available with Trip Pro

2018 ESC heart failure

152. Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure (PubMed)

Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure 30416736 2018 12 07 2050-3369 7 3 2018 Aug Arrhythmia & electrophysiology review Arrhythm Electrophysiol Rev Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure. 218-219 10.15420/aer.2018.7.3.L1 Theodoros Zografos Z eng Journal Article England Arrhythm Electrophysiol Rev 101637930 2050-3369 2018 11 13 6 0 2018 11 13 6 0 2018 11 13 6 1 ppublish 30416736 10.15420/aer (...) .2018.7.3.L1 PMC6141951 Circulation. 2013 Feb 5;127(5):613-23 23275383 Europace. 2012 Jan;14(1):81-91 21798880 ESC Heart Fail. 2018 Oct;5(5):965-976 29984912 Heart Rhythm. 2018 Mar;15(3):460-468 29107697 Pacing Clin Electrophysiol. 2006 Oct;29(10):1063-8 17038137 Arrhythm Electrophysiol Rev. 2018 Jun;7(2):103-110 29967682 N Engl J Med. 2013 Apr 25;368(17):1585-93 23614585 J Am Coll Cardiol. 1999 Feb;33(2):311-6 9973008 Arrhythm Electrophysiol Rev. 2017 Dec;6(4):159-160 29326829 Eur Heart J. 2015 Apr

Full Text available with Trip Pro

2018 Arrhythmia & electrophysiology review

153. Sex differences in outcomes of heart failure in an ambulatory, population-based cohort from 2009 to 2013 (PubMed)

Sex differences in outcomes of heart failure in an ambulatory, population-based cohort from 2009 to 2013 Heart failure remains a substantial cause of morbidity and mortality in women. We examined the sex differences in heart failure incidence, mortality and hospital admission in a population-based cohort.All Ontario residents who were diagnosed with heart failure in an ambulatory setting between Apr. 1, 2009, and Mar. 31, 2014, were included in this study. Incident cases of heart failure were (...) captured through physician billing using a validated algorithm. Outcomes were mortality and hospital admission for heart failure within 1 year of the diagnosis. Probability of death and hospital admission were calculated using the Kaplan-Meier method. The hazard of death was assessed using a multivariable Cox proportional hazard model.A total of 90 707 diagnoses of heart failure were made in an ambulatory setting during the study period (47% women). Women were more likely to be older and more frail

Full Text available with Trip Pro

2018 EvidenceUpdates

154. Heart failure

Heart failure Top results for heart failure - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for heart failure The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

155. Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study

Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study Factors associated with hospital emergency readmission and mortality rates in patients with heart failure or chronic obstructive pulmonary disease: a national observational study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry (...) - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Factors predicting mortality and readmission following admission with heart failure or chronic obstructive pulmonary disease were identified at both patient and hospital levels. {{author}} {{($index , , , & . Alex Bottle 1, * , Kate Honeyford 1 , Faiza

2018 NIHR HTA programme

156. Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation (PubMed)

Haemodynamic effects of percutaneous mitral valve edge‐to‐edge repair in patients with end‐stage heart failure awaiting heart transplantation Functional mitral regurgitation is complicating end-stage heart failure and potential heart transplantation by increasing pulmonary artery pressures. The aim of the present study was to investigate feasibility and haemodynamic effects of percutaneous mitral valve edge-to-edge repair using the MitraClip™ device in patients with end-stage heart (...) failure awaiting heart transplantation.In this retrospective study, we identified nine patients suffering from end-stage heart failure listed for heart transplantation in whom moderate-severe or severe functional mitral regurgitation was recognized and treated with percutaneous mitral valve edge-to-edge repair. Twenty-two patients listed for heart transplantation and presenting with moderate-severe or severe functional mitral regurgitation treated in the pre-MitraClip™ era served as controls. Patients

Full Text available with Trip Pro

2018 ESC heart failure

157. The effects of a low-carbohydrate diet on oxygen saturation in heart failure patients: a randomized controlled clinical trial. (PubMed)

The effects of a low-carbohydrate diet on oxygen saturation in heart failure patients: a randomized controlled clinical trial. Nutritional therapy in heart failure (HF) patients has been focused on fluid and sodium restriction with the aim of decreasing volume overload. However, these recommendations are not well established and sometimes controversial.To evaluate the effect of the consumption of a low-carbohydrate diet on oxygen saturation, body composition and clinical variables during two (...) months of follow-up in chronic, stable heart failure patients.In a parallel group randomized controlled clinical trial, 88 ambulatory patients were randomly assigned to a low-carbohydrate diet group (40% carbohydrates, 20% protein and 40% fats [12% saturated, 18% monounsaturated and 10% polyunsaturated]) or a standard diet group (50% carbohydrates, 20% protein and 30% fats [10% saturated, 10% monounsaturated and 10% polyunsaturated]) for two months. Diets were normocaloric in both groups. At baseline

Full Text available with Trip Pro

2018 Nutricion hospitalaria

158. Effect of the self-management education program on the quality of life in people with chronic heart failure: a randomized controlled trial (PubMed)

Effect of the self-management education program on the quality of life in people with chronic heart failure: a randomized controlled trial Chronic Heart Failure (CHF) is a syndrome that negatively affects a person's Quality of Life (QOL). The efficient self-management education program increases the individual's abilities and skills for following and participating in a long-term healthcare plan.The aim of this study was to determine the effect of the self-management education program on QOL (...) sessions followed for a 3-month period. The Iranian heart failure QOL questionnaire was used for data collection before and after the intervention. The independent-samples and paired-samples t-tests, Chi-square and Fisher exact tests were used for data analysis via the SPSS v.16 software. P<0.05 was considered statistically significant.No statistically significant differences were reported between the groups in terms of demographic and clinical characteristics, indicating that they were homogeneous

Full Text available with Trip Pro

2018 Electronic physician

159. Sacubitril–valsartan in heart failure and multimorbidity patients (PubMed)

Sacubitril–valsartan in heart failure and multimorbidity patients The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit the functionality of patients. Sacubitril-valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little evidence about the improvement on functionality. The aim of our study is to analyse the improvement of the functional class and the 6 min (...) an improvement in the NYHA functional class.Sacubitril-valsartan relieves symptoms and improves functional class prognostic risk of patients with advanced HFrEF and co-morbidity.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Full Text available with Trip Pro

2018 ESC heart failure

160. Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues (PubMed)

Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues Pulmonary hypertension (PH) is a common and severe complication of heart failure (HF). Consequently, HF is the leading cause of PH. For many years, specialists have attempted to better understand the pathophysiology of PH in HF, to define its prevalence and its impact on prognosis in order to improve the therapeutic management of these patients. Nowadays, despite the recent guidelines published (...) on the subject, several points remain unclear or debated, and until now, no study has demonstrated the efficacy of any treatment. The aim of this review is to report the evolution of the concepts on post-capillary PH (diagnosis, prevalence, prognosis, and therapeutics). The main issues are raised, focusing especially on the link between structural alterations and haemodynamic abnormalities, to discuss the possible reasons for treatment failures and future potential targets.© 2018 The Authors. ESC Heart

Full Text available with Trip Pro

2018 ESC heart failure